TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38143482

Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfers (CCT)
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS)
Number of subjects: 1809

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Navigator
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: CCT + SMS
Number of subjects: 1809

Group type: COMPARATOR
Intervention: SOC-Outreach
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Continuing SMS
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Stopping SMS
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Continuing CCT
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Stopping CCT
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Initial CCT escalated to navigator if lapse occurred
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Initial SMS escalated to navigator if lapse occurred
Number of subjects: 1809
Study: 38143760

Group type: EXPERIMENTAL
Intervention: Anti-CD5 CAR-T cells
Number of subjects: 1
Study: 38144428

Group type: EXPERIMENTAL
Intervention: High protein supplementation (60 g)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Moderate protein supplementation (20 g)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Carbohydrate placebo (PLA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Dietary control (CON)
Number of subjects: 122
Study: 38144487

Group type: EXPERIMENTAL
Intervention: Phasix mesh
Number of subjects: 84
Study: 38144515

Group type: EXPERIMENTAL
Intervention: Dietary weight loss and exercise program over 48 months
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1230
Study: 38144529

Group type: EXPERIMENTAL
Intervention: belantamab mafodotin
Number of subjects: 111
Study: 38145006

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive patients with taste disturbance
Number of subjects: 16

Group type: COMPARATOR
Intervention: Negative controls (fungiform papillae from patients before March 2020)
Number of subjects: 16
Study: 38145113

Group type: EXPERIMENTAL
Intervention: PyroHC (pyrotinib, trastuzumab, and chemotherapy)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: PyroHC (first-line treatment)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: PyroHC (in patients with brain metastases)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: PyroHC
Number of subjects: 135
Study: 38145229

Group type: EXPERIMENTAL
Intervention: Computer-based training for cognitive behavioral therapy (CBT4CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder (MOUD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 38145231

Group type: EXPERIMENTAL
Intervention: Multimodal AI system using ChatGPT and anterior segment images, smartphone-based, aiming for ≥90% sensitivity and ≥95% specificity for diagnosing and triaging ophthalmic diseases.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multimodal AI system using ChatGPT and anterior segment images, smartphone-based, validated across three locations.
Number of subjects: 100
Study: 38145474

Group type: EXPERIMENTAL
Intervention: Minimally invasive posterior spinal nonfusion (PSnF) surgery with bipolar one-way self-expanding rods (OWSER) system
Number of subjects: 14
Study: 38145714

Group type: EXPERIMENTAL
Intervention: High dietary fiber (HFib) intervention with daily snacks high in dietary fiber (10-12 g/day) for 18 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study: 38145715

Group type: EXPERIMENTAL
Intervention: Peer-supported dCBT intervention (SilverCloud)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Unsupported dCBT intervention (SilverCloud)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Provider-level outreach (using a clinic patient registry)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Inreach (traditional provider referral)
Number of subjects: 426
Study: 38145791

Group type: EXPERIMENTAL
Intervention: Irradiated PFT survivors
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Non-irradiated PFT survivors
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study: 38146133

Group type: EXPERIMENTAL
Intervention: Polysubstance use patterns; specific intervention details not available
Number of subjects: 0
Study: 38146234

Group type: EXPERIMENTAL
Intervention: Noninvasive auricular vagus nerve stimulation (AVNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham auricular vagus nerve stimulation
Number of subjects: 0
Study: 38146256

Group type: EXPERIMENTAL
Intervention: Oral anti-coagulants (OAC)
Number of subjects: 52530

Group type: EXPERIMENTAL
Intervention: OAC
Number of subjects: 52530

Group type: EXPERIMENTAL
Intervention: In-hospital rhythm control strategies (catheter ablation)
Number of subjects: 52530

Group type: EXPERIMENTAL
Intervention: In-hospital rhythm control strategies (electronic cardioversion)
Number of subjects: 52530

Group type: EXPERIMENTAL
Intervention: In-hospital rhythm control strategies (anti-arrhythmic drug use)
Number of subjects: 52530
Study: 38146531

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 0
Study: 38146651

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38146908

Group type: EXPERIMENTAL
Intervention: Aspirin continuation within 5 days before surgery (n=269)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Non-aspirin group (stopped aspirin no later than 5 days before surgery) (n=205)
Number of subjects: 474
Study: 38147031

Group type: EXPERIMENTAL
Intervention: Peer-delivered HIV self-testing (HIVST)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Peer-delivered PrEP
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Self-sampling for STI testing
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Peer psychosocial support
Number of subjects: 55
Study: 38147107

Group type: EXPERIMENTAL
Intervention: Single-parent families
Number of subjects: 2828

Group type: EXPERIMENTAL
Intervention: Stepfamilies
Number of subjects: 2828

Group type: EXPERIMENTAL
Intervention: Stepfamilies (3-10 years)
Number of subjects: 2828

Group type: EXPERIMENTAL
Intervention: Stepfamilies (11-17 years)
Number of subjects: 2828

Group type: COMPARATOR
Intervention: Traditional families
Number of subjects: 2828
Study: 38147137

Group type: EXPERIMENTAL
Intervention: Isatuximab 10 mg/kg weekly for 4 weeks then every 2 weeks for 8 weeks
Number of subjects: 23
Study: 38147153

Group type: EXPERIMENTAL
Intervention: Idarubicin-based transarterial chemoembolization (IDA-TACE)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Doxorubicin-based transarterial chemoembolization (DOX-TACE)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: IDA-TACE
Number of subjects: 128

Group type: COMPARATOR
Intervention: DOX-TACE
Number of subjects: 128
Study: 38147180

Group type: EXPERIMENTAL
Intervention: Surgical reconstructive therapy with adjunctive use of Er:YAG laser
Number of subjects: 24

Group type: COMPARATOR
Intervention: Surgical reconstructive therapy without adjunctive use of Er:YAG laser (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (laser and control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Surgical reconstructive therapy
Number of subjects: 24
Study: 38147268

Group type: EXPERIMENTAL
Intervention: Non-invasive pulsed radiofrequency (NipRF) therapy applied to the greater occipital nerve (GON)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Greater occipital nerve (GON) block under ultrasound guidance
Number of subjects: 0
Study: 38147281

Group type: EXPERIMENTAL
Intervention: Iron-whey-protein microspheres (14 mg daily, 25 mg daily, 50 mg daily) for 12 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Prior oral iron product
Number of subjects: 59
Study: 38147326

Group type: EXPERIMENTAL
Intervention: Intensive food-as-medicine program (providing healthy groceries for 10 meals per week, dietitian consultations, nurse evaluations, health coaching, and diabetes education for 1 year)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Intensive food-as-medicine program
Number of subjects: 465
Study: 38147413

Group type: EXPERIMENTAL
Intervention: HLA haplotype A*02:01-B*15:01-C*03:04-DRB1*04:01-DQB1*03:02
Number of subjects: 131

Group type: COMPARATOR
Intervention: Neuropathy without pain (control group)
Number of subjects: 131
Study: 38147491

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral scripts
Number of subjects: 0
Study: 38147525

Group type: EXPERIMENTAL
Intervention: GLPG3312 (Pan-SIK Inhibitor)
Number of subjects: 0
Study: 38147711

Group type: EXPERIMENTAL
Intervention: Written document and verbal information
Number of subjects: 60

Group type: COMPARATOR
Intervention: Verbal information only
Number of subjects: 60
Study: 38147816

Group type: EXPERIMENTAL
Intervention: Trastuzumab biosimilar (HLX02), pertuzumab, and chemotherapy
Number of subjects: 45
Study: 38147871

Group type: EXPERIMENTAL
Intervention: CAB + RPV (Q8W)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CAB + RPV (Q4W)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CAB + RPV
Number of subjects: 41
Study: 38148064

Group type: EXPERIMENTAL
Intervention: Vasopressin 0.2 IU/ml
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vasopressin 0.1 IU/ml
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vasopressin 0.05 IU/ml
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 39
Study: 38148327

Group type: EXPERIMENTAL
Intervention: SCT200 combined with SCT-I10A
Number of subjects: 21

Group type: COMPARATOR
Intervention: SCT200 monotherapy (from previous phase I study)
Number of subjects: 21
Study: 38148411

Group type: EXPERIMENTAL
Intervention: Bortezomib-based regimens
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Daratumumab-based regimens
Number of subjects: 170

Group type: COMPARATOR
Intervention: Other chemotherapy regimens
Number of subjects: 170
Study: 38148468

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (20 μg) for 15 minutes after internal mammary artery harvesting
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline inhalation for 15 minutes after internal mammary artery harvesting
Number of subjects: 100
Study: 38148664

Group type: EXPERIMENTAL
Intervention: Panel of 20 metabolites including lactate, cotinine, salicylate, 6 phosphatidylcholines, and 4 sphingomyelins.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Blood lactate, arginine, and proline metabolism.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 61
Study: 38148846

Group type: EXPERIMENTAL
Intervention: 150 min/wk of moderate-intensity aerobic exercise (low-dose)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 300 min/wk of moderate-intensity aerobic exercise (high-dose)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 39
Study: 38149026

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 19
Study: 38149073

Group type: EXPERIMENTAL
Intervention: Kombucha enriched with inulin (2.53 g/220 mL) and vitamins (B1 - 0.59 mg, B2 - 0.55 mg, B3 - 5.9 mg, B6 - 0.7 mg, folic acid - 81.4 μg/220 mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water
Number of subjects: 40
Study: 38149099

Group type: EXPERIMENTAL
Intervention: PyroH plus chemotherapy
Number of subjects: 333

Group type: COMPARATOR
Intervention: HP plus chemotherapy
Number of subjects: 333
Study: 38149261

Group type: EXPERIMENTAL
Intervention: Lived experience of seeking help for their own mental health conditions
Number of subjects: 4245

Group type: EXPERIMENTAL
Intervention: Lived experience of receiving medical treatment for a mental illness
Number of subjects: 4245

Group type: EXPERIMENTAL
Intervention: Lived experience of having a friend or family member affected by mental illness
Number of subjects: 4245

Group type: EXPERIMENTAL
Intervention: Being surrounded by colleagues who are less stigmatising
Number of subjects: 4245

Group type: EXPERIMENTAL
Intervention: Providing psychotherapy to patients
Number of subjects: 4245

Group type: EXPERIMENTAL
Intervention: Being open to case discussion, supervision, or Balint groups
Number of subjects: 4245

Group type: EXPERIMENTAL
Intervention: Actively participating in case discussion, supervision, or Balint groups
Number of subjects: 4245
Study: 38149403

Group type: EXPERIMENTAL
Intervention: Intravenous fosphenytoin 18 mg/kg (high dose)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous fosphenytoin 12 mg/kg (low dose)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 38149413

Group type: EXPERIMENTAL
Intervention: Dairy kefir
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo dairy drink
Number of subjects: 70
Study: 38149620

Group type: EXPERIMENTAL
Intervention: Microembolic signals (MES) detected using transcranial Doppler within 24 hours post-stroke.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 61
Study: 38149636

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 51
Study: 38149948

Group type: EXPERIMENTAL
Intervention: CD30.CAR-T therapy
Number of subjects: 26
Study: 38150009

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (900 mg/day)
Number of subjects: 11
Study: 38150126

Group type: EXPERIMENTAL
Intervention: Machine learning model based on AU17 (chin raising) and AU20 (lip stretching)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Machine learning model based on all AUs
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Merged ML model utilizing gaze, eye landmarks, head position, and facial landmarks
Number of subjects: 155

Group type: COMPARATOR
Intervention: AUs known to be associated with pain in awake patients
Number of subjects: 155
Study: 38150232

Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder (MOUD) treatment offered at intake, throughout incarceration, and upon release.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incorporation of requirements into medical provider contracts to screen all people entering jails for OUD.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sample contractual language for medical provider proposals to integrate MOUD treatment.
Number of subjects: 0
Study: 38150256

Group type: EXPERIMENTAL
Intervention: Topical 1.62% testosterone gel
Number of subjects: 5204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5204
Study: 38150260

Group type: EXPERIMENTAL
Intervention: High-intensity care with higher doses of GDMT
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Medium doses of GDMT
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: High doses of GDMT
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Higher GDMT doses at week 2
Number of subjects: 515
Study: 38150310

Group type: COMPARATOR
Intervention: Usual care, face-to-face visits every sixth month
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Remote monitoring, monthly digital registration of patient-reported outcomes
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Patient-initiated care, self-monitoring, no planned visits during the study period
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 240
Study: 38150444

Group type: EXPERIMENTAL
Intervention: End-of-life communication strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semi-structured in-depth interviews and focus group discussions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thematic analysis
Number of subjects: 0
Study: 38150492

Group type: EXPERIMENTAL
Intervention: Elevated plasma donor-derived cell-free DNA (dd-cfDNA) measured by the Prospera test in AMR biopsies.
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Elevated plasma dd-cfDNA in AKI biopsies.
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Elevated plasma dd-cfDNA in TCMR biopsies.
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Elevated plasma dd-cfDNA in biopsies classified as MMDx Normal and NRNI.
Number of subjects: 604
Study: 38151173

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 38151258

Group type: EXPERIMENTAL
Intervention: Bronchial rheoplasty (BR) with the RheOx system
Number of subjects: 21
Study: 38151280

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) from a lean donor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 38151309

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 23562
Study: 38151311

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 211

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 211
Study: 38151313

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 11957
Study: 38151376

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Nagi Mobility Scale during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Basic Activities of Daily Living during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index score as a predictor of mobility impairment
Number of subjects: 232
Study: 38151388

Group type: EXPERIMENTAL
Intervention: epcoritamab monotherapy
Number of subjects: 157
Study: 38151502

Group type: EXPERIMENTAL
Intervention: Momentum Distillation-enhanced Composite Transformer Attention (MD-CTA) model
Number of subjects: 395

Group type: COMPARATOR
Intervention: Convolution Neural Network (CNN)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: MD-CTA model
Number of subjects: 395

Group type: COMPARATOR
Intervention: CNN
Number of subjects: 395
Study: 38151533

Group type: COMPARATOR
Intervention: Higher levels of proteins in M_IT compared to F_NL and F_IT.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dietary protein to fiber ratio (P/F) in M_IT.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Plant protein to animal protein (PP/AP) and PP to total proteins ratio in F_NL.
Number of subjects: 19
Study: 38151605

Group type: EXPERIMENTAL
Intervention: QRS complex features during the first month of life
Number of subjects: 17450
Study: 38151682

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Local excision
Number of subjects: 53
Study: 38151766

Group type: EXPERIMENTAL
Intervention: Trauma plasma-derived exosomes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Male trauma plasma-derived exosomes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Female trauma plasma-derived exosomes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Elective total hip arthroplasty (THA)
Number of subjects: 15
Study: 38151867

Group type: EXPERIMENTAL
Intervention: Minimal disability trajectory
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Mild disability trajectory
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Moderate disability trajectory
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Severe disability trajectory
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Post COVID-19 condition
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Cognition
Number of subjects: 422
Study: 38152017

Group type: EXPERIMENTAL
Intervention: Tutivia
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Tutivia + serum creatinine at biopsy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Serum creatinine at biopsy alone
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Model cut-off of 50 (scale 0-100)
Number of subjects: 151
Study: 38152395

Group type: EXPERIMENTAL
Intervention: ipilimumab and nivolumab
Number of subjects: 58
Study: 38152404

Group type: EXPERIMENTAL
Intervention: Antifungal treatment
Number of subjects: 419
Study: 38152412

Group type: EXPERIMENTAL
Intervention: ixoberogene soroparvovec (ixo-vec) gene therapy
Number of subjects: 30
Study: 38152462

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM) 400 mg/70 kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Psilocybin (10, 20, 30 mg/70 kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 20
Study: 38152640

Group type: EXPERIMENTAL
Intervention: 10% neutral buffered formalin (NBF) fixation for 1-30 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10% neutral buffered formalin (NBF) fixation for 30-60 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10% neutral buffered formalin (NBF) fixation for 60-90 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10% neutral buffered formalin (NBF) fixation for 90+ days (up to 2 years)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10% neutral buffered formalin (NBF) fixation for all groups
Number of subjects: 80
Study: 38152664

Group type: EXPERIMENTAL
Intervention: Pneumococcal urinary antigen tests
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Viral and bacterial analysis from nasopharyngeal swabs
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Routine diagnostic care
Number of subjects: 518

Group type: COMPARATOR
Intervention: Controls without symptoms
Number of subjects: 518
Study: 38152697

Group type: EXPERIMENTAL
Intervention: Onalespib (260 mg/m) + Paclitaxel (standard dose)
Number of subjects: 31
Study: 38152876

Group type: EXPERIMENTAL
Intervention: 400,000 ASCs injected into each limboconjunctival quadrant and suspended over the cornea for 20 minutes, followed by amniotic membrane patching.
Number of subjects: 8
Study: 38152892

Group type: EXPERIMENTAL
Intervention: NAFLD-specific digital health program
Number of subjects: 38